Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility
Autor: | Daniel J. Lodge, David Aguilar, Andrea Giuffrida |
---|---|
Rok vydání: | 2018 |
Předmět: |
medicine.medical_specialty
Psychosis medicine.medical_treatment Hippocampus Regular Research Articles Rats Sprague-Dawley WIN55 212-2 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interneurons Internal medicine parvalbumin Synthetic cannabinoids medicine Animals Pharmacology (medical) Amphetamine Pharmacology Methylazoxymethanol acetate Behavior Animal Cannabinoids business.industry Dopaminergic Neurons Age Factors methylazoxymethanol acetate URB597 electrophysiology medicine.disease Endocannabinoid system Rats Up-Regulation 3. Good health 030227 psychiatry Disease Models Animal Psychiatry and Mental health Endocrinology chemistry Schizophrenia Central Nervous System Stimulants Disease Susceptibility Cannabinoid business 030217 neurology & neurosurgery Endocannabinoids medicine.drug |
Zdroj: | International Journal of Neuropsychopharmacology |
ISSN: | 1469-5111 1461-1457 |
DOI: | 10.1093/ijnp/pyy003 |
Popis: | Background Epidemiological studies recognize cannabis intake as a risk factor for schizophrenia, yet the majority of adolescents who use marijuana do not develop psychosis. Similarly, the abuse of synthetic cannabinoids poses a risk for psychosis. For these reasons, it is imperative to understand the effects of adolescent cannabinoid exposure in susceptible individuals. Methods We recently developed a novel rodent model of schizophrenia susceptibility, the F2 methylazoxymethanol acetate rat, where only a proportion (~40%) of rats display a schizophrenia-like phenotype. Using this model, we examined the effects of adolescent synthetic cannabinoid exposure (0.2 mg/kg WIN55, 212-2, i.p.) or adolescent endocannabinoid upregulation (0.3 mg/kg URB597, i.p.) on dopamine neuron activity and amphetamine sensitivity in adulthood. Results Adolescent synthetic cannabinoid exposure significantly increased the proportion of susceptible rats displaying a schizophrenia-like hyperdopaminergic phenotype after puberty without producing any observable alterations in control rats. Furthermore, this acquired phenotype appears to correspond with alterations in parvalbumin interneuron function within the hippocampus. Endocannabinoid upregulation during adolescence also increased the proportion of susceptible rats developing an increase in dopamine neuron activity; however, it did not alter the behavioral response to amphetamine, further emphasizing differences between exogenous and endogenous cannabinoids. Conclusions Taken together, these studies provide experimental evidence that adolescent synthetic cannabinoid exposure may contribute to psychosis in susceptible individuals. |
Databáze: | OpenAIRE |
Externí odkaz: |